» Articles » PMID: 34249316

Best Management of Irritable Bowel Syndrome

Overview
Specialty Gastroenterology
Date 2021 Jul 12
PMID 34249316
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction which can have a considerable impact on quality of life. Following diagnosis, timely and evidence-based management is vital to the care of patients with IBS, aiming to improve outcomes, and enhance patient satisfaction. Good communication is paramount, and clinicians should provide a clear explanation about the disorder, with a focus on exploring the patient's own beliefs about IBS, and a discussion of any concerns they may have. It should be emphasised that symptoms are often chronic, and that treatment, while aiming to improve symptoms, may not relieve them completely. Initial management should include simple lifestyle and dietary advice, discussion of the possible benefit of some probiotics, and, if this is unsuccessful, patients can be referred to a dietician for consideration of a low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) diet. Antispasmodics and peppermint oil can be used first-line for the treatment of abdominal pain. If patients fail to respond, central neuromodulators can be used second-line; tricyclic antidepressants should be preferred. Loperamide and laxatives can be used first-line for treating diarrhoea and constipation, respectively. Patients with constipation who fail to respond to laxatives should be offered a trial of linaclotide. For patients with diarrhoea, the 5-hydroxytryptamine- receptor agonists alosetron and ramosetron appear to be the most effective second-line drugs. Where these are unavailable, ondansetron is a reasonable alternative. If medical treatment is unsuccessful, patients should be referred for psychological therapy, where available, if they are amenable to this. Cognitive behavioural therapy and gut-directed hypnotherapy are the psychological therapies with the largest evidence base.

Citing Articles

Irritable Bowel Syndrome: A Hallmark of Psychological Distress in Women?.

Marano G, Traversi G, Pola R, Gasbarrini A, Gaetani E, Mazza M Life (Basel). 2025; 15(2).

PMID: 40003686 PMC: 11856493. DOI: 10.3390/life15020277.


Risk factors for developing irritable bowel syndrome: systematic umbrella review of reviews.

Sulaimi F, Ong T, Tang A, Quek J, Pillay R, Low D BMC Med. 2025; 23(1):103.

PMID: 39985070 PMC: 11846330. DOI: 10.1186/s12916-025-03930-5.


Serotoninergic Mechanisms of Action in the Relaxant Properties of Saccharomyces boulardii CNCM I-745 on the Intestine.

Girard P, Verleye M, Castagne V Dig Dis Sci. 2024; 70(1):191-202.

PMID: 39661276 PMC: 11761163. DOI: 10.1007/s10620-024-08786-y.


The integration of complementary and integrative health and whole person health in gastrointestinal disorders: a narrative review.

Craven M, Thakur E Transl Gastroenterol Hepatol. 2024; 9:75.

PMID: 39503019 PMC: 11535803. DOI: 10.21037/tgh-23-121.


Dietary Interventions in Irritable Bowel Syndrome: A Systematic Review of Clinical Outcomes, Microbiota Changes, and Inflammatory Markers.

Shams M, Ahmed J, Umar A, Rehman A, Sohail K, Javed B Cureus. 2024; 16(9):e70568.

PMID: 39483931 PMC: 11524984. DOI: 10.7759/cureus.70568.


References
1.
Dixon-Woods M, Critchley S . Medical and lay views of irritable bowel syndrome. Fam Pract. 2000; 17(2):108-13. DOI: 10.1093/fampra/17.2.108. View

2.
Fritscher-Ravens A, Pflaum T, Mosinger M, Ruchay Z, Rocken C, Milla P . Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin E. Gastroenterology. 2019; 157(1):109-118.e5. DOI: 10.1053/j.gastro.2019.03.046. View

3.
Kassinen A, Krogius-Kurikka L, Makivuokko H, Rinttila T, Paulin L, Corander J . The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007; 133(1):24-33. DOI: 10.1053/j.gastro.2007.04.005. View

4.
Lewis-Fernandez R, Lam P, Lucak S, Galfalvy H, Jackson E, Fried J . An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder. J Clin Psychopharmacol. 2016; 36(6):710-715. DOI: 10.1097/JCP.0000000000000599. View

5.
Canavan C, West J, Card T . Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014; 40(9):1023-34. DOI: 10.1111/apt.12938. View